Klaria announces positive pre-clinical proof-of-concept study results with the Cannabinoid CBD, superior data on both tested outcome measures demonstrated
Today, Klaria announces positive results in a pre-clinical Proof-of-Concept (PoC) study conducted with the cannabinoid CBD, formulated in the company’s proprietary alginate transmucosal film. The results demonstrate that Klaria’s technology has the potential to significantly improve the delivery of cannabis-derived compounds, particularly with respect to rapid, exact and reproducible dosing. As such, it could be of great benefit to patients and other stakeholders across the cannabis industry.
The PoC study was positive on both key measures, which were 1) time to clinically/medically relevant blood concentration of CBD with the film formulation vs an oral formulation and 2) bioavailability of CBD with the film formulation vs an oral formulation. Specifically, the time to medically relevant concentration was reduced by more than 50% to less than 20 minutes for the film vs over 40 minutes for the oral formulation. The amount of CBD absorbed from the film was more than twice as high as that absorbed from the oral formulation. The study was conducted by Porsolt, one of the leading preclinical CROs in the world.
Scott Boyer, Klaria Pharma’s CEO said: “The future of pharmaceutical cannabis is in so called ”edibles”, or orally eaten products. Smoking is simple not an acceptable delivery method for medical products. The two important downsides of edibles are 1) the uptake through the stomach is slow, with up to one hour before therapeutic concentrations are achieved in the blood and 2) the so-called bioavailability, or uptake, through the stomach is both variable and inefficient. Only a small amount of the total amount given orally is taken up by the body. The data we are presenting today from our preclinical PoC study shows that our technology solves both of these problems. We get an uptake that is significantly faster and more efficient than the uptake observed for oral administration – these combined properties translate into a more precise and reproducible therapy. With these strong data, we have taken a large step forward in Klaria’s cannabinoid program.”
Moreover, the cannabinoid formulation patent filings that were announced on March 7thof this year have been amended to include the novel data. In addition, the company has initiated discussions with cannabis-focused companies regarding potential licensing agreements for the technology.
These data demonstrate that Klaria’s technology has the potential to significantly improve the delivery of cannabis-derived compounds. Thus, it could be of great benefit across the cannabis industry which is currently suffering from issues related to the lack of rapid and reliable delivery of the active substances.
For more information, visit the Klaria Pharma Holding website klaria.com or contact:
Scott Boyer, CEO Klaria Pharma Holding AB (publ)
scott.boyer@klaria.com
Tel: +46 8-446 42 99 / +46 730-71 64 62
This is Klaria Pharma Holding AB
Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.